Abstract:Background Diffuse large B-cell lymphoma (DLBCL) is characterized by its aggressive nature and resistance to standard chemotherapy, necessitating the development of new therapeutic approaches. Histone acetylation, a crucial epigenetic modification, is globally decreased in DLBCL. Chidamide, a histone deacetylase (HDACs) inhibitor, has shown promise in certain lymphomas but its effectiveness in DLBCL remains under investigation. Methods RNA-seq and gene enrichment analysis were performed to identify chidamide's impact on the biological processes in DLBCL. The key factor influencing chidamide sensitivity was determined through correlation analysis, utilizing gene expression levels from the Cancer Cell Line Encyclopedia and IC50 values of four HDAC inhibitors across multiple cancer cell lines sourced from the Genomics of Drug Sensitivity database. Histone acetylation levels, HAT and HDAC enzyme activity analysis, and co-immunoprecipitation were performed to investigate the underlying mechanism through which BCL6 influences chidamide sensitivity. A search among small molecule drugs in clinical investigation aimed to find drugs inhibiting BCL6 to enhance DLBCL sensitivity to chidamide. Synergy between HDAC and BCL6 inhibition was explored through synergistic effects, ubiquitination, and proteasomal degradation analysis. DLBCL mouse models were utilized to evaluate the therapeutic potential of combining chidamide and lenalidomide in vivo. Additionally, chidamide's effects on macrophage polarization were investigated through RNA-seq analysis of M1, M2, and chidamide-treated M2 macrophages. Results Chidamide exhibited potent suppression of DLBCL both in vitro and in vivo (Figure 1A), exerting a significant impact on diverse biological processes in DLBCL. BCL6 inhibited chidamide-induced histone acetylation by recruiting HDACs, leading to drug resistance in DLBCL cells. Lenalidomide could target BCL6 degradation through the ubiquitination pathway and restored the sensitivity of drug-resistant DLBCL to chidamide (Figure 1B). Additionally, chidamide had an impact on the tumor microenvironment. Chidamide inhibited the activity of M2-like tumor-associated macrophages and redirected the polarization of macrophages toward the M1 phenotype. Moreover, we conducted a single-arm multicenter clinical trial to evaluate the safety and efficacy of chidamide in combination with lenalidomide in DLBCL. Conclusions These findings highlighted HDACs as a viable therapeutic strategy for DLBCL, providing valuable insights into chidamide's global impact on the disease. Furthermore, BCL6 was a pivotal determinant of chidamide sensitivity and a reliable biomarker for treatment response. Integrating HDAC and BCL6 inhibition held potential for personalized and effective DLBCL treatments.

[Effect of Chidamide on Human B Lymphoma Cell Lines and Its Mechanisms].

Growth inhibitory effects of Chidamide on breast cancer cells

Chidamide, a Histone Deacetylase Inhibitor, Induces Growth Arrest and Apoptosis in Multiple Myeloma Cells in a Caspase-Dependent Manner.

[Effects of Berbamine on K562 Cells and Its Mechanisms in Vitro and in Vivo].

Chidamide in Relapsed or Refractory Peripheral T Cell Lymphoma: A Multicenter Real-World Study in China

Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation

Antitumor activity of Chidamide in hepatocellular carcinoma cell lines

Effect of domestic decitabine influence on morphology, proliferation and CD80 expression in mouse lymphoma/leukemia cell line EL4 cells

Enhancing Therapeutic Efficacy: Harnessing the Synergy of Histone Deacetylase and BCL6 Inhibition in DLBCL

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma

[Effect of HDAC Inhibitor Chidamide on PD-L1 Expression in Peripheral T-Cell Lymphoma]

Targeting HDACs for diffuse large B-cell lymphoma therapy

Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma

Therapeutic Effects Of The Novel Subtype-Selective Histone Deacetylase Inhibitor Chidamide On Myeloma-Associated Bone Disease

Chidamide, A Novel Histone Deacetylase Inhibitor, Inhibits Laryngeal Cancer Progression in vitro and in vivo

Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia

Chidamide triggers pyroptosis in T-cell lymphoblastic lymphoma/leukemia via the FOXO1/GSDME axis

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy

Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma

4-Chlorobenzoyl Berbamine Induces Apoptosis And G2/M Cell Cycle Arrest Through The Pi3k/Akt And Nf-Kappa B Signal Pathway In Lymphoma Cells